# Semaglutide (Ozempic, Wegovy, Rybelsus): research overview > Semaglutide (Ozempic, Wegovy, Rybelsus): research overview — Research Peptide Fundamentals | mybiopeptides — Semaglutide in the Research Peptide Fundamentals series on research peptides: one molecule, three trademarks — Ozempic, Wegovy and Rybelsus — and one generic name. What the -glutide ending signals, the codes that came first, and what the trials measured. **01 — THE GENERIC-NAME CASE** A 31-amino-acid molecule that answered to three company codes before a standards body called it semaglutide, and to three trademarks after — while its ending quietly encodes its receptor family. ## The short version Semaglutide — the molecule marketed under the trademarks Ozempic, Wegovy and Rybelsus — is a laboratory-made copy of a hormone the gut releases after a meal, redesigned to last far longer in the body. The natural hormone is called **GLP-1**, and it tells the pancreas to release insulin, tells the stomach to empty more slowly, and tells the brain that eating can stop. Natural GLP-1 breaks down in about two minutes. Semaglutide survives for roughly a week. That durability is engineered, not accidental. Two of the amino acids in the chain were swapped to block the enzyme that normally chops the hormone up, and a fatty chain was bolted on so the molecule clings to a blood protein instead of being filtered out by the kidneys. The name is engineered too. The ending **-tide** is the convention that marks a peptide. The longer ending **-glutide** narrows it further, to the GLP-1 family. So the name alone places the molecule in a class before a reader has looked at a single study — which is exactly what a generic naming system is built to do. ## What it is: the name that arrived last Structurally, semaglutide is a 31-amino-acid acylated analogue of human glucagon-like peptide-1, sharing roughly 94% of its sequence with the natural hormone. Three modifications do the work. At position 8, alanine is replaced by alpha-aminoisobutyric acid, which blocks cleavage by the enzyme dipeptidyl peptidase-4. At position 34, lysine is replaced by arginine. That leaves a single lysine at position 26, and it is acylated with a C18 fatty di-acid side chain through a spacer — a lipid arm that binds reversibly but strongly to serum albumin, shielding the peptide from renal clearance. The once-weekly interval is a direct consequence of that arm. Notice that the structural description is itself a naming system. *Aib8*, *K26*, *R34* are positional labels, and a reader fluent in them can reconstruct most of the molecule from a sentence. This is the most precise naming register available and the least portable: it identifies the molecule unambiguously and communicates nothing to anyone outside the field. The generic name arrived after the codes. The corpus behind this page records the same compound under **NNC0113-0217**, **NN9535** and **OG217SC** — development identifiers of the kind assigned inside a research programme, before a molecule has earned an entry in the international generic-name list. A single compound accumulating several such codes is entirely normal; different formulations and different phases of a programme often carry different numbers. Alongside those sit the class descriptors: *GLP-1 receptor agonist*, *incretin mimetic*, *long-acting GLP-1 analogue*, *acylated GLP-1 analogue*. These are not names for this molecule. They are names for a category this molecule belongs to, and several other compounds satisfy each of them. Confusing a class descriptor with a compound name is one of the commonest errors in writing about peptides. Then comes the register that makes semaglutide the most instructive name on this entire site: the trademark. This one molecule is marketed under **three** of them — **Ozempic**, **Wegovy** and **Rybelsus**. That multiplication is the whole lesson. A trademark does not name a compound. It names a *product* — a particular formulation, at particular strengths, licensed for particular indications — and one compound can therefore support as many trademarks as its manufacturer has products to sell. The corpus behind this page records semaglutide in two delivery forms, a once-weekly subcutaneous injection and a once-daily oral tablet, across a set of approved indications spanning diabetes, weight management, cardiovascular risk and liver disease. Which trademark attaches to which of those combinations is a commercial and regulatory matter that this page does not attempt to map, because the source material for this site does not record it. So the four registers behave very differently under pressure. The chemical description is unique and unreadable. The company codes were provisional and are now largely historical. The trademarks are plural, jurisdiction-bound, owned, and attached to products rather than to matter. Exactly one label — **semaglutide** — identifies the molecule itself, holds across every manufacturer, formulation and country, and is the name that will still be correct when the patents expire and the trademarks proliferate further. That is what a generic name is *for*, and it is why this site uses it as the primary name throughout. Naming the trademarks here is a factual matter, not a commercial one. mybiopeptides has no relationship with any manufacturer, sells nothing, and supplies nothing. ## How it works Semaglutide is a long-acting agonist at the glucagon-like peptide-1 receptor. Because of the position-8 substitution and the albumin-binding side chain, it resists degradation and circulates for roughly a week rather than minutes. Through that receptor it potentiates glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release from alpha cells, and slows gastric emptying. The weight effect, though, is mostly central. In rodents, semaglutide reached the brainstem, area postrema, hypothalamic arcuate nucleus and parabrachial nucleus, reduced food intake and altered food preference — and did so without decreasing energy expenditure [6]. In other words the molecule works by changing how much an animal wants to eat, not by raising the rate at which it burns fuel. The receptor targets that matter therefore span the pancreas, the hypothalamus, the brainstem, gastric smooth muscle and vagal afferents, and cardiovascular and renal tissue. ## What the research shows The trial record is unusually large for a peptide, and it runs well past weight. **Weight.** In the STEP 1 randomised trial, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline at week 68, against -2.4% with placebo, in 1,961 adults with overweight or obesity and without diabetes — a treatment difference of roughly 12.4 percentage points [4]. **Cardiovascular outcomes.** SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Once-weekly semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, with a hazard ratio of 0.80 (95% CI 0.72-0.90; P<0.001) [3]. The earlier SUSTAIN-6 trial, in 3,297 people with type 2 diabetes at high cardiovascular risk, found a comparable direction of effect (HR 0.74; 95% CI 0.58-0.95) [7]. **Kidney outcomes.** In FLOW, 3,533 participants with type 2 diabetes and chronic kidney disease received once-weekly semaglutide 1.0 mg or placebo. Major kidney-disease events — kidney failure, a fall in eGFR of at least 50%, or death from kidney or cardiovascular causes — occurred less often on semaglutide, with a hazard ratio of 0.76 (95% CI 0.66-0.88) [2]. **Head to head.** In SURMOUNT-5, an open-label trial in 751 adults with obesity, tirzepatide produced greater mean weight loss than semaglutide at 72 weeks: -20.2% against -13.7%, a statistically significant difference (P<0.001) [1]. That comparison is discussed further on the **[tirzepatide page](/tirzepatide)**. A dedicated safety review concluded that semaglutide's overall risk-benefit profile in type 2 diabetes is favourable, with adverse effects dominated by transient gastrointestinal events — nausea in roughly one third of patients — an increased risk of biliary disease, and pancreatic and thyroid-cancer signals on which definitive conclusions cannot yet be drawn given the low incidence [5]. ## Reported effects, cautions and safety What follows in this first part is **anecdotal, not clinical evidence** — it is what people describe in reviews and research-use communities, summarised without any dose attached, and it should not be read as a measured outcome. By far the most frequently reported benefit is a quieting of what users call *food noise*: the constant background preoccupation with the next meal simply goes quiet, often within the first weeks. People commonly report feeling full sooner and eating substantially smaller portions, and many describe this as the single most significant change. Closely related is a sharp drop in cravings — sugar and sweets especially, with fried and greasy food frequently becoming actively unappealing. Weight loss is reported by the overwhelming majority, typically described as steady over months and attributed to eating far less rather than to exercising more. Among people using it for type 2 diabetes, markedly improved blood-sugar and HbA1c readings are a common theme. A recurring secondary observation, discussed widely in patient communities, is that the desire to drink alcohol fades alongside food cravings. The reported downsides cluster in the gut. Nausea is the single most-mentioned adverse effect, peaking early and after each dose increase and often easing within a week or two. A distinctive complaint is foul-smelling sulphurous burping, which reviewers say appears far more often than official lists suggest. Disrupted bowel habits — constipation and diarrhoea, sometimes alternating — are among the most mentioned digestive problems, along with acid reflux. Fatigue in the first days after an injection, headaches and light-headedness linked to inadequate hydration, taste changes and food aversions, injection-site reactions, and hair shedding with facial gauntness attributed to rapid weight loss all appear regularly. **Documented cautions.** Gastrointestinal intolerance during dose escalation is the leading cause of discontinuation, and it is mechanistic rather than incidental — the slowed gastric emptying that produces it is part of how the drug works [5]. A boxed warning covers thyroid C-cell tumours, derived from rodent studies at supratherapeutic exposures; human data have not established a clear increase in thyroid cancer, but a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a contraindication on the strength of the animal finding [5]. Acute pancreatitis is a class warning, and treatment is conventionally stopped if pancreatitis is suspected [5]. Gallbladder and biliary disease are increased, attributed largely to the rate and magnitude of weight loss rather than direct toxicity [5]. In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent (HR 1.76; 95% CI 1.11-2.78), concentrated among patients with pre-existing retinopathy undergoing rapid correction of blood glucose [7]. Body-composition substudies show a meaningful share of the weight lost is lean mass, raising a sarcopenia concern particularly in older adults, and stopping treatment is followed by substantial regain — which frames this as a chronic rather than curative intervention. Pregnancy is a contraindication. One further controversy is worth recording because it bears directly on names. During the declared shortage, compounding pharmacies produced semaglutide, and regulators documented dosing errors, adverse events requiring hospitalisation, and products whose active ingredient was unverified or not of pharmaceutical grade. A product labelled with the generic name is not thereby the approved product. ## Where it fits in Research Peptide Fundamentals Semaglutide is this site's specimen of a fully resolved naming history — a compound that travelled the whole route from internal code to international generic name to registered trademark — three of those, in the end — and that therefore carries a label from every register at once. The useful lesson is the shape of the ending. **-tide** is the convention that marks the molecule as a peptide; **-glutide** narrows it to the GLP-1 analogue subfamily. The corpus behind this hub names dulaglutide only in passing, as a comparator in a trial, but it is a second specimen of the same pattern — and that is precisely the point of a stem system. A reader who has never encountered a particular -glutide can still place it in a receptor family on sight. Hold that observation, because the **[next page](/tirzepatide)** is about a molecule that ends in -tide and conspicuously does not end in -glutide, and about why that gap in the name corresponds to a real difference in what the compound binds. --- mybiopeptides reads the peptide literature by its labels — an independent editorial digest of published research, not a clinic, not a pharmacy, and not a source of dosing advice.